Entrada Therapeutics (TRDA) Capital Expenditures (2020 - 2025)

Entrada Therapeutics' Capital Expenditures history runs 6 years deep, the most recent figure standing at $1.0 million for Q4 2025.

• In Q4 2025, Capital Expenditures rose 108.2% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at -$103000.0 (down 111.89% YoY), while the FY2025 annual figure was $1.0 million, up 85.89% from the prior year.
• Capital Expenditures was $1.0 million for Q4 2025 at Entrada Therapeutics, up from -$1.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q1 2023 to a low of -$2.9 million in Q3 2023.
• Historically, Capital Expenditures has averaged $340894.7 across 5 years, with a median of $838000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures sank 291.2% in 2023, then soared 649.45% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $1.3 million in 2021, then sank by 258.17% to -$2.1 million in 2022, then surged by 95.65% to -$91000.0 in 2023, then jumped by 649.45% to $500000.0 in 2024, then soared by 108.2% to $1.0 million in 2025.
• The last three Capital Expenditures figures came in at $1.0 million (Q4 2025), -$1.1 million (Q2 2025), and $1.1 million (Q1 2025), per Business Quant data.